Company logos shown on QuarterCharts are trademarks of their respective owners and are used solely for identification of the company whose data is displayed. Their use does not imply endorsement, sponsorship, or affiliation with the trademark owners. Full trademarks policy.
| Line item | FY2026 (Q1+Q2) + FY2025 (Q3+Q4) | FY2025 (Q1+Q2) + FY2024 (Q3+Q4) |
|---|---|---|
| Revenue | $8.02M | $36.74M |
| COGS | $15.3M | $33.77M |
| Gross Profit | — | $2.97M |
| R&D | — | — |
| SG&A | — | — |
| D&A | $2.32M | $2.72M |
| Other OpEx | $60.67M |
QuarterCharts · SEC EDGAR data · MEDS · Comparing FY2026 (Q1+Q2) + FY2025 (Q3+Q4) vs FY2025 (Q1+Q2) + FY2024 (Q3+Q4)
| — |
| Operating Income | — | $247.98K |
| Interest Exp. | $5.93M | $3.11M |
| Other Non-Op | $12.08M | $42.44M |
| Pretax Income | — | — |
| Tax | — | — |
| Net Income | — | — |
